Metabolic syndrome and cardiovascular disease
=============================================

Along with the growing epidemic of obesity and chronic diseases, the risk of atherosclerosis, as well as cardiovascular disease (CVD) morbidity and mortality, are increasing markedly ([@b76-vhrm-4-0825]). [@b58-vhrm-4-0825] noted that several risk factors for CVD commonly cluster together, and he recognized them as a disease, named syndrome X, currently known as metabolic syndrome (MS). Insulin resistance (IR) is considered the primary cause of associated cardiovascular risk factors and the probable mechanism linking all the MS comprising features, such as visceral obesity, glucose intolerance, type 2 diabetes mellitus (T2DM), arterial hypertension, atherogenic dyslipidemia, proinflammatory, and prothrombotic state ([@b64-vhrm-4-0825]).

Viscerally distributed adipose tissue, rather than subcutaneous fat, plays a major role in this process ([@b76-vhrm-4-0825]). Adipose tissue is controlled by several signals, including insulin and growth hormone (GH), and has been considered as an endocrine organ ([@b44-vhrm-4-0825]). Adipocytes secrete inflammatory mediators and adipokines (comprising leptin and adiponectin), that regulate endothelial function, atherogenesis, and energetic balance. Adipokines also activate intracellular pathways, regulating the subacute inflammatory state associated with obesity, and the development of IR and T2DM ([@b66-vhrm-4-0825]). Endothelial dysfunction (reflected principally by microalbuminuria) is associated with MS components, and is present in patients suffering from atherosclerosis. Overall, it is not clear yet whether IR is cause or consequence of endothelial dysfunction ([@b51-vhrm-4-0825]). To date, an increased risk of CVD death is more pronounced when MS itself is present. However, each individual component of MS may also confer increased occurrence of CVD. So far, the more components of MS that are evident, higher is the cardiovascular mortality rate ([@b33-vhrm-4-0825]).

Defining metabolic syndrome
===========================

Several groups have recommended clinical criteria for the diagnosis of MS in adults ([@b3-vhrm-4-0825]; [@b8-vhrm-4-0825]; [@b5-vhrm-4-0825]; NCEP--ATP III 2001; [@b18-vhrm-4-0825]; [@b20-vhrm-4-0825]; [@b22-vhrm-4-0825]; [@b34-vhrm-4-0825]). Definition data regarding different criteria are summarized in [Table 1](#t1-vhrm-4-0825){ref-type="table"}.

In what concerns the pediatric population, there are several difficulties in determining MS features. Some authors have proposed modified adult criteria, taking into account child specific cutoff values and percentiles ([@b14-vhrm-4-0825]; [@b15-vhrm-4-0825]; [@b17-vhrm-4-0825]; [@b77-vhrm-4-0825]; [@b37-vhrm-4-0825]). Insulin sensitivity, an important diagnostic condition for MS, is difficult to obtain, especially in pediatric patients. To date, hyperinsulinemic clamp has been considered the gold-standard for insulin evaluation, but this is a complicated method to be applied in children. Moreover, insulin sensitivity changes with age and puberty, while it is negatively correlated with visceral obesity. Data for percentiles of waist circumference that are specific to ethnic origin are becoming increasingly available ([@b78-vhrm-4-0825]), and have been suggested in MS definition criteria in pediatric patients, rather than body mass index (BMI). In addition, BMI was converted to standard deviation scores (SDS) or percentiles for comparisons, with the basis of the [@b46-vhrm-4-0825] international reference. Blood pressure percentiles were determined according to the [@b48-vhrm-4-0825], while lipid levels were analyzed with the basis of different existing criteria ([@b4-vhrm-4-0825]; [@b28-vhrm-4-0825]). On the other hand, the International Diabetes Federation (IDF) has recently redefined MS in children and adolescents, and has proposed requiring parameters in absolute values, rather than age-related percentile cutoffs. Moreover, it has also been suggested that MS should not be diagnosed in children younger than 10 years, even though visceral obesity should call for attention ([@b78-vhrm-4-0825]). See [Table 2](#t2-vhrm-4-0825){ref-type="table"}.

Pediatric patients at high-risk: Attention to childhood cancer survivors
========================================================================

The prevalence of MS and risk assessment is quite diverse, depending on the diagnostic criteria and assortment of population, but there is full agreement that it is clearly growing in overweight adults and pediatric patients ([@b22-vhrm-4-0825]). Notwithstanding, several pediatric conditions predisposing to the syndrome, as well MS comprising traits, should be identified earlier in childhood, in order to prevent CVD in adult life ([@b78-vhrm-4-0825]). Typical examples are homozygous hypercholesterolemia, diabetes mellitus, chronic kidney disease, congenital heart disease, heart transplantation, Kawasaki disease, chronic inflammatory disease, systemic lupus erythematosus, rheumatoid arthritis, and cancer treatment during childhood ([@b38-vhrm-4-0825]).

In the last twenty years, along with the better care committed to children with cancer, the establishment of chemotherapy (CT) and the advances in radiotherapy (RT), survival rates have greatly improved. Consequently, the number of patients that reach adulthood presenting some treatment-related health problems or mortality due to CVD is increasing continuously ([@b53-vhrm-4-0825]). According to a statement developed by the American Heart Association along with the Council for Cardiovascular Disease in the Young, based on the study of several pediatric states and their risk for CVD, post-cancer treatment survivors were classified as tier III, which means increased cardiovascular risk factors, with epidemiological evidence for manifest CVD early in adult life, but after 30 years of age ([@b38-vhrm-4-0825]). Survivors of specific pediatric cancer groups, particularly acute lymphocytic leukemia (ALL), central nervous system (CNS) tumors, sarcomas, lymphomas, disseminated testicular cancer, neuroblastomas, Wilms tumors, and following bone marrow transplantation (BMT), are recognized to present clinical features of MS, and therefore increased risk factors for CVD, such as visceral obesity, IR, glucose intolerance, dyslipidemia, arterial hypertension, and endothelial dysfunction ([@b27-vhrm-4-0825]; [@b53-vhrm-4-0825]; [@b40-vhrm-4-0825]; [@b52-vhrm-4-0825]; [@b24-vhrm-4-0825]; [@b50-vhrm-4-0825]; [@b35-vhrm-4-0825]; [@b57-vhrm-4-0825]; [@b74-vhrm-4-0825]; [@b75-vhrm-4-0825]; [@b31-vhrm-4-0825]).

Metabolic syndrome and cancer: What comes first?
================================================

Different studies have shown that cancer and several chronic diseases may have some risk factors in common, considered features of MS, such as obesity, hyperinsulinemia, and IR. Nonetheless, it remains controversial if such risk factors are cause or consequence of chronic diseases, including cancer ([@b32-vhrm-4-0825]).

The association between diabetes mellitus and cancer was reported more than 100 years ago ([@b25-vhrm-4-0825]), and population studies have shown increased evidence that MS is increasing worldwide, in parallel with an increasing of cancer incidence ([@b79-vhrm-4-0825]). Moreover, diabetes and obesity have been recognized as risk factors for the development of breast, endometrial, colorectal, and pancreatic carcinomas. To date, the association between diabetes, obesity, and cancer incite speculations about the mechanisms linking IR and adiposity, components of MS, and the development of certain types of cancer. However, the relation between MS (and its consequent biochemical derangements) and cancer still remains unexplained ([@b25-vhrm-4-0825]).

Carcinogenesis is multifactorial, and depends not only on metabolic disturbances, but also on the inherited genetic background. Part of the carcinogenic effect could be attributed to adiposity, through hyperinsulinism, and additional mechanisms, that may include chronic inflammation and oxidative stress associated with obesity ([@b25-vhrm-4-0825]; [@b32-vhrm-4-0825]). Insulin itself may also be an important factor linking IR to cancer ([@b32-vhrm-4-0825]). Previous statements have shown ample evidence suggesting that high levels of insulin (due to IR) increase insulin-like growth factor (IGF)-1 bioavailability by means of suppression of IGF binding protein 1 and 3 (IGFBP-1 and 3). IGF-1 has a role in promoting carcinogenesis and IGF-1 receptor is crucial for tumor transformation, and survival of malignant cells. Moreover, specific polymorphisms in certain genes encoding proteins involved in IGF-signaling pathway, including IGF-1 itself, are associated with variation in cancer risk ([@b25-vhrm-4-0825]; [@b56-vhrm-4-0825]; [@b79-vhrm-4-0825]).

On the other hand, it remains highly controversial if carcinogenesis could possibly contribute to the development of MS in survivors of various malignancies. This is still little understood, but there are several speculations over it. The neoplasms may probably cause changes on insulin sensitivity, lipid metabolism, inflammatory mediators, and adipokines, which may be aggravated by anticancer therapies, including CT and RT. Thus far, the best biological model to study the relationship between cancer and the components of MS is cancer cachexia, which affects more than a half of cancer patients ([@b63-vhrm-4-0825]). Cancer cachexia is considered a complex and multifactorial metabolic disorder involving features of anorexia, asthenia, lipolysis, changes in body composition, systemic inflammation, IR, and may predispose to long-term metabolic disturbances, and decreased lean body mass and muscles, that remain insulin resistant, analogous to the state proposed by the Barker hypothesis after intrauterine growth retardation ([@b9-vhrm-4-0825]; [@b63-vhrm-4-0825]).

Metabolic syndrome features in childhood cancer survivors
=========================================================

Thus far, the mechanisms behind increased cardiovascular risk factors in childhood cancer survivors are not clarified yet. Notwithstanding, there is a strong possibility that some pathways, different from those in non-cancer populations, may be activated in childhood cancer survivors, underlying mechanisms for weight gain and IR. These include various hormones deficiencies, changes on insulin sensitivity, lipid metabolism, inflammatory mediators and adipokines, as well as reduced physical activity, which may be altered by various cancer therapies. Local treatments, such as surgery and RT, may lead to multiple endocrine deficiencies and, consequently, to MS comprising features. Systemic treatments, like CT, may contribute to MS in several ways: damage of endocrine organs or nonhormonal systems, such as magnesium metabolism, as well as endothelial, and adipose tissue dysfunction ([@b51-vhrm-4-0825]; [@b38-vhrm-4-0825]).

Regarding childhood cancer survivors at risk for MS, and consequently considered at risk for premature development of CVD, we described the possible mechanisms determining MS, focusing on specific pediatric cancer groups, in which weight gain, endocrine and metabolic disturbances are especially prevalent.

Mechanisms of metabolic syndrome in childhood cancer survivors
==============================================================

Growth hormone deficiency and intima-media thickness
----------------------------------------------------

Growth hormone (GH) deficiency in childhood cancer survivors may be attributed to the tumor itself, depending on the location in the hypothalamic-pituitary region, or to an adverse effect of treatment, comprising cranial RT, and/or CT. GH is implicated not only in growth regulation, but also in metabolism. GH deficiency frequently induces MS-like disorders, such as hypertriglyceridemia, low HDL-cholesterol, coagulopathy, and hypertension. Despite evidence linking GH deficiency to the components of MS and CVD, the relationship between the syndrome and GH secretion status has not been established yet. Thus far, two important conditions related to GH deficiency, IR and endothelial dysfunction, justify especial considerations ([@b51-vhrm-4-0825]).

So far, increased intima-media thickness (IMT), an intermediate marker for CVD, has been described in the common carotid arteries of untreated children and adults with GH deficiency, and has been inversely correlated with IGF-1 levels ([@b72-vhrm-4-0825]; [@b70-vhrm-4-0825]). In what concerns oncologic patients, no differences were recorded in artery thickness between ALL survivors regardless of cranial RT at dose up to 24 Gy ([@b53-vhrm-4-0825]; [@b40-vhrm-4-0825]). In contrast, an increased IMT in the carotid bulb of childhood CNS tumors survivors who received high-dose cranial RT (\>45 Gy) was described by [@b27-vhrm-4-0825]. In conclusion, IMT seems to be positively correlated with cranial RT dose employed, and negatively correlated with IGF-1 levels, which in turn reflect GH status.

To date, GH replacement therapy in both oncologic and nononcologic GH-deficient patients can improve morphological and functional changes predisposing to CVD, particularly body composition ([@b11-vhrm-4-0825]; [@b13-vhrm-4-0825]; [@b70-vhrm-4-0825]). Nevertheless, the positive effects of GH replacement while on therapy usually do not persist after GH is discontinued, and depend on the period of replacement. A short-term GH replacement (12 months) induces favorable outcome, comprising metabolic parameters and body composition, however the beneficial effects on vascular damage (IMT) are only seen after long-term GH therapy (2 years) ([@b70-vhrm-4-0825]). Finally, IMT was not prospectively evaluated while on GH therapy in the oncologic population ([@b11-vhrm-4-0825]).

Thyroid dysfunction
-------------------

Thyroid dysfunction is an important adverse late-effect of cancer therapy, especially after neck RT, as CT alone does not possibly impair thyroid function. Several malignancies, encompassing tumors of CNS requiring craniospinal RT (medulloblastomas), lymphomas or neck tumors requiring locally administered RT, as well as following conditioning total body irradiation (TBI) before BMT, are at risk for thyroid dysfunction ([@b51-vhrm-4-0825]; [@b21-vhrm-4-0825]).

The hypothyroid state affects the cardiovascular system through both an influence on the heart and adverse effects on serum lipids, increasing the risk of development of CVD ([@b51-vhrm-4-0825]). Nevertheless, subclinical hypothyroidism, a state with elevated thyroid stimulating hormone (TSH) concentrations (\>5.0 mIU/L) and normal levels of thyroxin (T4) and triiodothyronine (T3) in asymptomatic subjects, commonly presented in long-term survivors of cancer, was not associated with increased risk for CVD ([@b51-vhrm-4-0825]). According to the European Organisation for Research and Treatment of Cancer database, in-field RT against aggressive non-Hodgkin's lymphomas, consistently treated with doxorubicin-based CT, was related to hypothyroidism, but not to CVD ([@b45-vhrm-4-0825]).

Gonadal failure
---------------

Despite the continuous improvement of cancer treatment protocols, gonadal failure is a frequent adverse effect in long-term cancer survivors, which may result in hormonal production impairment (hypogonadism), and in the risk of developing MS. It may occur as a consequence of gonadectomy, direct damage of RT to gonads, and/or CT-comprising alkylant drugs (busulfan, cyclophosphamide and iphosphamide) or platinum compounds (carboplatin and cysplatin). So far, estrogens and testosterone are known to influence body composition, lipid metabolism, vascular tone, and blood pressure ([@b51-vhrm-4-0825]; [@b21-vhrm-4-0825]; [@b62-vhrm-4-0825]).

In male gonads, oligo or azoospermia may occur after low-dose RT or alkylating CT, whereas Leydig cells and testosterone production are relatively resistant to damage. On the other hand, in females, RT and cytotoxic treatment may partially or definitively affect both, reproductive function and hormonal production, resulting in premature ovarian failure (POF), with amenorrhea or irregular menses ([@b51-vhrm-4-0825]; [@b10-vhrm-4-0825]; [@b62-vhrm-4-0825]). According to the Childhood Cancer Survivor Study (CCSS), the risk factors to POF in females are: older age at tumor diagnosis, Hodgkin's lymphoma, pelvic RT at or above 10 Gy or alkylating agents at ages of 13--20 years ([@b69-vhrm-4-0825]). Thus, CT after pubertal onset seems to be more destructive to the ovaries compared to therapy during childhood ([@b62-vhrm-4-0825]). Overall, hormone deficiency in both sexes, rather than infertility, is somehow connected to the risk of developing MS features.

Magnesium deficiency
--------------------

Systemic anticancer therapies can cause derangement of nonhormonal systems, leading to metabolic disorders, comprising magnesium (Mg^+2^) levels. To date, Mg^+2^ levels play a role in insulin sensitivity and vascular tone. Generally, hypomagnesemia has been implicated in the development of metabolic disorders, IR and hypertension, increasing the risk of atherosclerosis and CVD ([@b51-vhrm-4-0825]).

Hypomagnesemia is a common effect following cytotoxic agent, particularly cysplatin, but its clinical importance needs to be better evaluated. Possible symptoms of hypomagnesemia are undistinguished from symptoms related to the underlying disease or from the CT-induced symptoms ([@b51-vhrm-4-0825]; [@b30-vhrm-4-0825]). Moreover, after initiation of treatment for ALL, rapid recovery in bone formation, which results in the movement of extracellular Mg^+2^ into the skeleton through bone formation, may be an important contributor to hypomagnesemia ([@b23-vhrm-4-0825]).

Other causes
------------

Vulnerable-child syndrome, lack of adequate physical activity due to damage to the muscles or nerves following CT or RT, altered behavior, energy utilization, and sleep patterns, as well as stress, may also contribute to MS comprising features. Physical inactivity further increases the risk of CVD, osteoporosis, and all-cause mortality. Sleepiness and narcolepsy were reported in craniopharyngioma patients, exacerbating hypothalamic obesity, and were associated with deficiency of orexin and melatonin ([@b62-vhrm-4-0825]). Exercise may suppress inflammatory responses and improves insulin sensitivity, rates of protein synthesis and antioxidant activities ([@b19-vhrm-4-0825]). Although CT agents may also cause adipose tissue derangement, thus far little is known about this statement.

Mild hyperhomocystinemia is a recently recognized risk factor in the development of CVD, leading to endothelial dysfunction and development of atherosclerosis. It is most commonly secondary to polymorphisms of enzymes involved in homocysteine (Hcy) metabolism, aggravated by the employment of methotrexate, which induces Hcy spikes and endothelial damage ([@b55-vhrm-4-0825]).

Acute lymphocytic leukemia
==========================

Acute lymphocytic leukemia (ALL) is the most common childhood malignancy, and it has been considered an important model to study the metabolic disorders and their relationship to the oncologic disease. Studies from the CCSS have reported an increased risk of all-cause mortality, cardiovascular-related mortality, cerebrovascular accidents, and chronic health conditions in long-term survivors of childhood ALL ([@b43-vhrm-4-0825]).

The association of obesity and cranial RT is well-established ([@b55-vhrm-4-0825]). From the CCSS, ALL survivors who have received \>20 Gy cranial RT (frequently 24 Gy) were at increased risk of overweight/obesity, especially females treated at a young age (\<5 years) ([@b54-vhrm-4-0825]). Other studies have also confirmed this association of cranial RT and obesity ([@b68-vhrm-4-0825]). Excessive weight gain during ALL treatment is usually related to steroids effects and CNS treatment on appetite regulation, as well as less energy expenditure. Nevertheless, these factors do not fully explain overweight in this group of patients ([@b16-vhrm-4-0825]). Early adiposity rebound (AR) is an additional mechanism that might contribute to obesity in survivors of ALL. The AR is the period of childhood (typically between 5 and 7 years) when BMI and other indexes of adiposity begin to increase after reaching their nadir ([@b59-vhrm-4-0825]). Leptin regulation disorder and leptin resistance have also been hypothesized to play a role in the development of obesity in ALL survivors. Leptin is an important adiposity index during and after ALL therapy as it correlates positively with BMI ([@b6-vhrm-4-0825]; [@b1-vhrm-4-0825]; [@b67-vhrm-4-0825]). In addition, leptin receptor polymorphism may also influence obesity in female survivors of childhood ALL, particularly those exposed to cranial RT ([@b60-vhrm-4-0825]). On the other hand, most children treated for ALL do not receive cranial RT, or RT dose employed may vary between 12 and 18 Gy (low-dose). Whether CT only or low-dose cranial RT are related to the development of obesity is controversial, but this association has been greatly reported by various previous statements ([@b6-vhrm-4-0825]; [@b59-vhrm-4-0825]; [@b16-vhrm-4-0825]; [@b57-vhrm-4-0825]).

Additionally, young adult survivors of childhood ALL are also at risk for MS traits, such as visceral adiposity, dyslipidemia, IR, and hypertension. While CT predisposes to features of MS in ALL survivors, cranial RT increases this predisposition ([@b73-vhrm-4-0825]; [@b53-vhrm-4-0825]; [@b40-vhrm-4-0825]; [@b36-vhrm-4-0825]; [@b24-vhrm-4-0825]; [@b35-vhrm-4-0825]; [@b75-vhrm-4-0825]). All these statements strongly linked the prevalence of MS features to GH deficiency and in turn to cranial RT, even though obesity, and MS traits (as well as GH deficiency) have also been described in patients treated with CT and corticosteroids only ([@b39-vhrm-4-0825]).

Central nervous system tumors
=============================

Obesity and multiple pituitary hormone deficiencies are common complications after treatment of CNS tumors. To date, the major risk factors that predict the development of obesity in CNS tumors survivors are, as follows: hypothalamic location, extent of surgery, hypothalamic irradiation exceeding 51 Gy, and the presence of hypothalamic-pituitary deficiencies, particularly GH deficiency ([@b41-vhrm-4-0825]; [@b2-vhrm-4-0825]).

[@b27-vhrm-4-0825] described an altered risk profile for CVD as elevated systolic blood pressure, altered body composition, and a less favorable lipid profile in long-term survivors of childhood CNS tumors (medulloblastoma, astrocitoma, ependymoma, craniopharyngioma and nasopharynx carcinoma), who received cranial RT exceeding 45 Gy. The altered metabolic profile, as well as a larger IMT in the carotid artery bulb, were more pronounced in a subgroup with GH deficiency due to cranial RT, so that these changes may be attributed to GH deficiency and predate the development of symptomatic atherosclerosis. Similarly, the existing statements concerning hyperphagia and uncontrolled hypothalamic obesity secondary to craniopharyngioma involve patients treated with either surgery or RT, and correlate findings to GH deficiency due to hypothalamic damage. According to [@b71-vhrm-4-0825], post-craniopharyngioma surgery in children may increase the risk for MS, including IR due to excess weight gain and GH deficiency. However, other possible contributing mechanisms include lack of sensitivity to endogenous leptin ([@b61-vhrm-4-0825]), vagally mediated hyperinsulinemia ([@b41-vhrm-4-0825]), autonomic imbalance ([@b41-vhrm-4-0825]), as well as reduced physical activity ([@b26-vhrm-4-0825]).

Sarcomas
========

Recently, an increased prevalence of MS traits, comprising hypertension, hypertriglyceridemia, and male visceral abdominal obesity, has been described in pediatric sarcomas survivors (predominantly Ewings), treated with multi-agent CT, and with or without RT ([@b31-vhrm-4-0825]). Taking into account the NCEP--ATP III criteria (three or more MS traits), there were no differences between the prevalence of MS comparing the study cohort and general population, but young survivors, aged less than 40 years, appear to be more affected ([@b31-vhrm-4-0825]). This statement concurs with the one stated by the American Heart Association along with the Council for Cardiovascular Disease in the Young, suggesting that post-cancer treatment survivors exhibit epidemiological evidence for manifest CVD early in adult life, and after 30 years of age ([@b38-vhrm-4-0825]). There was no association between MS traits and markers of inflammation and coagulation in pediatric sarcomas survivors. On the other hand, testosterone levels declined as the number of MS features increased, similarly to the condition described to disseminated testicular cancer survivors ([@b52-vhrm-4-0825]; [@b31-vhrm-4-0825]). No association between GH deficiency and the occurrence of MS traits were observed, although GH deficiency was seen in survivors with or without cranial RT. Physical inactivity due to altered ambulatory function, a consequence of surgical resection and/or RT to thrunk, pelvic and lower extremity may also contribute for the development of MS in pediatric sarcomas survivors ([@b31-vhrm-4-0825]).

Other types of cancer
=====================

Features of MS have also been described in disseminated testicular cancer, lymphomas, neuroblastomas, and Wilms tumors ([@b52-vhrm-4-0825]; [@b57-vhrm-4-0825]; [@b31-vhrm-4-0825]). The mechanisms involved are similar to those described in other types of cancer. While the association between lymphomas, neuroblastomas, Wilms tumors and MS traits are not often reported, much attention has been given to the relationship between testicular cancer and the features of MS. To date, long-term survivors of disseminated testicular cancer treated with cisplatin-based CT presented with dyslipidemia, hypertension, microalbuminuria, overweight, IR, and increased plasma levels of endothelial and inflammatory marker proteins, which might progress to more severe endothelial dysfunction, and overt atherosclerosis. Testosterone deficiency, rather than other dysfunctions, may play a role in the development of MS in this particular group of patients ([@b51-vhrm-4-0825]; [@b52-vhrm-4-0825]).

Bone marrow transplantation
===========================

Bone marrow transplantation (BMT), including allogeneic and autologous transplantation of stem cells from bone marrow, peripheral blood, and umbilical cord blood, has increased dramatically in recent years. BMT is applied mainly to treat poor-prognosis leukemia and solid tumors, but it is also effective in curing hematological, immunological, genetic, and metabolic nonhematological diseases. As long as the number of BMT increases, the number of long-term survivors of BMT is steadily increasing, and so endocrine effects usually occur as a consequence of pretransplant conditioning regimens. The most common endocrine dysfunctions following BMT are growth disturbances, thyroid dysfunction, gonadal failure, and osteoporosis ([@b65-vhrm-4-0825]).

Currently, it is becoming clear from a number of studies among adult and pediatric recipients of BMT that they are also at risk of developing abdominal adiposity, IR and other features of MS, such as impaired glucose tolerance, T2DM, dyslipidemia, and hypertension. Early unexplained mortality in adult recipients of BMT has raised concerns regarding accelerated cardiovascular risk in this group of patients ([@b29-vhrm-4-0825]; [@b12-vhrm-4-0825]; [@b50-vhrm-4-0825]; [@b65-vhrm-4-0825]; [@b7-vhrm-4-0825]; [@b74-vhrm-4-0825]). The relative risk is influenced by the underlying disease, previous treatments (cranial RT or alkylating CT agents), post-BMT treatments, older age and advanced pubertal stage at BMT, GH deficiency, and genetic predisposition (family history of dyslipidemia and T2DM) ([@b65-vhrm-4-0825]). TBI, untreated hypogonadism, and abdominal adiposity (a known feature of GH deficiency), were considered risk factors for the development of hyperinsulinemia, impaired glucose tolerance, and T2DM in pubertal and adult survivors, having TBI the strongest association ([@b50-vhrm-4-0825]). Additionally, a waist to height ratio greater than 0.5 in prepubertal subjects may represent an early and simple clinical marker for the later development of metabolic disturbance ([@b50-vhrm-4-0825]). To date, TBI as a preparative therapy for BMT is the key role in the genesis of IR, as stated by a large multicenter study that included survivors of both pediatric and adult BMT. The risk of developing T2DM was 3 times as likely to occur in BMT recipients as in a control group, and this risk was associated with TBI ([@b7-vhrm-4-0825]). Nonetheless, the mechanisms underlying this still remain unclear. TBI has been shown to alter mitochondrial function in muscle, liver, and pancreas, resulting in the development of IR, and T2DM. Other mechanisms related to the immunologic and inflammatory effects of BMT may play a role in the development of such features. To date, the effect of TBI on the function of adipose tissue in secreting adipokines has not been studied yet ([@b50-vhrm-4-0825]; [@b7-vhrm-4-0825]).

Interventions for cardiovascular risk reduction
===============================================

Hormonal supplementation and primary or secondary prevention of endothelial dysfunction are recommended to prevent MS and early atherosclerosis in long-term cancer survivors ([@b51-vhrm-4-0825]).

Primary prevention comprises prevention of hormonal deficiencies and/or direct endothelial damage through more limited surgery, CT dose reduction, avoidance of unnecessary gonadotoxic CT, and the administration of alternative drugs.

Secondary prevention encompasses the following: supplementation of hormonal deficiencies (thyroid, gonadal and/or GH); treatment of therapy-related endothelial dysfunction (IR, dyslipidemia, Mg^+2^ supplementation); and, finally, screening for the occurrence of MS, and treatment when appropriate ([@b51-vhrm-4-0825]).

Complementary interventional recommendations for cardiovascular risk identification and reduction were developed as a consensus by a writing group convened under the joint direction of the American Heart Association's Expert Panel on Population and Prevention Science and the Council for Cardiovascular Disease in the Young, and an algorithm was developed outlining the risk factor evaluation, management, and therapeutic recommendations ([@b38-vhrm-4-0825]). See [Figure 1](#f1-vhrm-4-0825){ref-type="fig"} and [Table 3](#t3-vhrm-4-0825){ref-type="table"}.

Concluding remarks
==================

The prevalence and pathogenesis of MS in long-term survivors of cancer, the significance of this syndrome, as well as the relationship between MS and the development of CVD after cancer treatment, have to be clarified yet. However, if MS plays an important role in the development of CVD after cancer treatment, this syndrome might be a major target for intervention during follow-up of cancer survivors. The following observations must be considered:

1.  Oncologists who treat childhood cancer survivors, and particularly those who provide primary care to adult survivors, should be aware of the potential for long-term hormonal deficiencies and adverse cardiovascular and diabetes risk profiles as a consequence of cancer treatment;

2.  Some specific cancer groups predisposing to MS traits, such as ALL, CNS tumors, lymphomas, sarcomas, testicular cancer, and following BMT, as well as RT or alkylating drugs regimens, must call for attention in order to early detect and treat any metabolic alteration or features of MS secondary to therapy;

3.  Attempts to prevent the problem of early AR in ALL patients are indicated in the interests of prevention of later obesity. These efforts might take the form of encouraging a more active lifestyle during the first years of therapy;

4.  Hypothalamic obesity often results in devastating metabolic and psychosocial complications, requiring provision of dietary and behavioral modifications, encouragement of regular physical activity, psychological counseling, as well as antiobesity drugs;

5.  Alternative conditioning therapies for BMT can be considered without compromising survival, reducing the risk of metabolic abnormality. Early detection of abdominal adiposity and/or hormonal deficiency may allow dietary, and lifestyle measures;

6.  Therapeutic lifestyle change, with emphasis on weight reduction, constitutes first-line therapy. In patients in whom lifestyle changes fail to reverse metabolic risk factors, consideration should be given to treating specific abnormalities with drugs, according to current treatment guidelines;

7.  Overall, further research is still necessary to define the epidemiology, risk factors, and mechanisms behind the development of metabolic disorders in survivors of pediatric cancers, particularly those involving endothelial and adipose tissue dysfunction.
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![Risk stratification and treatment algorithm of childhood cancer survivors (Adapted from [@b38-vhrm-4-0825]).\
**Abbreviations:** CVD, cardiovascular disease; M, male; F, female; BMI, body mass index; BP, blood pressure; FG, fasting glucose; HbA1C, glycated hemoglobin.](vhrm-4-0825f1){#f1-vhrm-4-0825}

###### 

Metabolic syndrome definition in adults according to different criteria (Adapted from [@b22-vhrm-4-0825])

  Risk factors           WHO (1998)                                                                   EGIR (1999)                                                               NCEP--ATP III (2001)                                                       AACE (2003)                                                                                                     [@b34-vhrm-4-0825]
  ---------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  **Requirement**        T2DM , impaired fasting glucose, IGT or IR (HOMA-IR) + ≥2 of the following   Hiyperinsulinemia or IR + ≥2 of the following                             ≥3 of the following                                                        Depends on clinical judgment based on risk factors as following[^\*^](#tfn2-vhrm-4-0825){ref-type="table-fn"}   Central obesity + ≥2 of the following
  **Blood pressure**     Antihypertensive drug and/or ≥140/90 mmHg with no treatment                  ≥140/90 mmHg or antihypertensive drug                                     ≥130/85 mmHg                                                               ≥130/85 mmHg                                                                                                    Antihypertensive drug or ≥130/85 mmHg
  **Triglycerides**      ≥150 mg/dL                                                                   ≥180 mg/dL                                                                ≥150 mg/dL                                                                 ≥150 mg/dL                                                                                                      ≥150 mg/dL
  **HDL-cholesterol**    M: \<35 mg/dL F: \<39 mg/dL                                                  \<40 mg/dL                                                                M: \<40 mg/dL F: \<50 mg/dL                                                M: \<40 mg/dL F: \<50 mg/dL                                                                                     M: \<40 mg/dL F: \<50 mg/dL
  **Central obesity**    BMI \>30 kg/m^2^ and/or M: W/H \>0.90 F: W/H \>0.85                          M: W ≥94 cm F: W ≥80 cm                                                   M: W \>102 cm F: W \>88 cm                                                 BMI ≥25 kg/m^2^ M: W \>102 cm F: W \>88 cm                                                                      M: W ≥94 cm F: W ≥80 cm
  **Microalbuminuria**   ≥20 μg /min                                                                  \-                                                                        \-                                                                         \-                                                                                                              \-
  **Glucose/insulin**    T2DM, impaired fasting glucose, IGT or IR (HOMA-IR)                          Fasting glucose ≥110 mg/dL[^‡^](#tfn4-vhrm-4-0825){ref-type="table-fn"}   Fasting glucose ≥110 mg/dL [^‡^](#tfn4-vhrm-4-0825){ref-type="table-fn"}   Fasting glucose 110--125 mg/dL[^‡^](#tfn4-vhrm-4-0825){ref-type="table-fn"} or IGT                              Fasting glucose ≥100 mg/dL (OGTT recommended) or previous T2DM

**Abbreviations:** WHO, World Health Organisation ([@b3-vhrm-4-0825]); EGIR, European Group for the Study of Insulin Resistance ([@b8-vhrm-4-0825]); NCEP--ATP III, National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III 2001); AACE, American College of Endocrinology/American Association of Clinical Endocrinologist ([@b18-vhrm-4-0825]); IDF, [@b34-vhrm-4-0825]; T2DM, type 2 diabetes mellitus (fasting glucose \>126 mg/dL); IGT, Impaired glucose tolerance[^†^](#tfn3-vhrm-4-0825){ref-type="table-fn"}; IR, insulin resistance; HOMA-IR, homeostasis model assessment; M, male; F, female; BMI, body mass index; W, waist; H, hip; W/H, waist to hip ratio; OGTT, oral glucose tolerance test.

**Notes:** ^\*^Other risk factors: polycystic ovary syndrome, sedentary lifestyle, advancing age, ethnic groups having high risk for T2DM or cardiovascular disease;

^†^IGT: OGTT post-2 h glucose \>140 mg/dL and \<200 mg/dL;

^‡^American Diabetes Association ([@b5-vhrm-4-0825]). However, a cutpoint of ≥100 mg/dL has been recently established, and should be applicable for identifying the lower boundary to define an elevated glucose as one criterion for the metabolic syndrome ([@b20-vhrm-4-0825]).

###### 

Metabolic syndrome definition in children and adolescents according to different criteria (Adapted from [@b37-vhrm-4-0825]; [@b78-vhrm-4-0825])

  Risk factor           [@b14-vhrm-4-0825]                                        [@b15-vhrm-4-0825]            [@b17-vhrm-4-0825]                [@b77-vhrm-4-0825]            IDF 2007
  --------------------- --------------------------------------------------------- ----------------------------- --------------------------------- ----------------------------- ---------------------------------------------------------
  **Requirement**       3 out of 5 of the following                               3 out of 5 of the following   3 out of 5 of the following       3 out of 5 of the following   BMI ≥90th percentile + ≥2 of the following
  **Age (years)**       12--19                                                    8--13                         12--19                            4--20                         10--16
  **Blood pressure**    ≥90th percentile or antihypertensive drug                 \>90th percentile             \>90th percentile                 \>95th percentile             Systolic blood pressure ≥130 mmHg or diastolic ≥85 mmHg
  **Triglycerides**     ≥110 mg/dL                                                ≥90th percentile              ≥100 mg/dL                        ≥95th percentile              ≥150 mg/dL
  **HDL-cholesterol**   ≤40 mg/dL                                                 ≤10th percentile              M^\*^: \<45 mg/dL F: \<50 mg/dL   \<5th percentile              \<40 mg/dL
  **Central obesity**   BMI ≥95th percentile W ≥90^th^ percentile                 W ≥90th percentile            W \>75th percentile               BMI ≥2 SDS                    W \>90th percentile
  **Glucose/insulin**   Fasting glucose ≥110 mg/dL^‡^ IGT, T2DM or IR (HOMA-IR)   IGT                           Fasting glucose ≥110 mg/dL^‡^     IGT or IR (HOMA-IR)           Fasting glucose ≥100 mg/dL (OGTT recommended) or T2DM

**Abbreviations:** IDF, International Diabetes Federation ([@b78-vhrm-4-0825]); BMI, body mass index; W, waist; IGT, impaired glucose tolerance^†^; T2DM, type 2 diabetes mellitus; IR, insulin resistance; HOMA-IR, homeostasis model assessment; M, male; F, female; SDS, standard deviation score; OGTT, oral glucose tolerance test.

**Notes:** ^†^IGT: OGTT post-2 h glucose \>140 mg/dL and \<200 mg/dL; ^\*^Males 15--19 yr; ^‡^American Diabetes Association ([@b5-vhrm-4-0825]). However, a cutpoint of ≥100 mg/dL has been recently established, and should be applicable for identifying the lower boundary to define an elevated glucose as one criterion for the metabolic syndrome ([@b20-vhrm-4-0825]).

###### 

Treatment recommendations for childhood cancer survivors (Adapted from [@b38-vhrm-4-0825])

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Growth/diet**
  Calculate BMI percentile for gender/height[^a^](#tfn8-vhrm-4-0825){ref-type="fn"}Age-appropriate reduced-calorie training for child and family, but adequate calories for growthTotal fat \<30% of calories, saturated fat \<10% of calories, cholesterol \<300 mg/dL, avoid *trans* fats
  **Blood pressure**
  BP measurement/interpretation for age/gender/height[^b^](#tfn9-vhrm-4-0825){ref-type="fn"}If BP = 90 to 95th percentile or \>120 × 80 mmHg (3 separate occasions within 1 month): decrease calorie intake and increase exerciseIf initial BP \>95th percentile (within 1 week) or \>95th percentile during 6-months follow-up: pharmacological therapy per Fourth Task Force recommendations[^c^](#tfn10-vhrm-4-0825){ref-type="fn"}
  **Lipids[^d^](#tfn11-vhrm-4-0825){ref-type="fn"}**
  If initial LDL-cholesterol \>160mg/dL: diet with \<30% fat, \<7% saturated fat, cholesterol \<200 mg/dL, avoidance of *trans* fats for 6 monthsWeight-loss management and exercise recommendations if overweight/obeseIf repeat LDL \>160 mg/dL and child \>10 yr: statin therapy with LDL goal of 130 mg/dLIf initial TG \>150 to 400 mg/dL: low carbohydrate and low-fat dietIf TG \>700 to 1000 mg/dL, initial or follow-up: fibrate or niacin if \>10 yr
  **Glucose[^e^](#tfn12-vhrm-4-0825){ref-type="fn"}**
  If fasting glucose = 100 to 126 mg/dL: reduced-calorie diet, increased activity over 6 monthsIf repeat: insulin-sensitizing medicationCasual glucose \>200 mg/dL or fasting glucose \>126 mg/dL = diabetes mellitus = endocrine referral, maintain HbA1C \<7%
  **Smoking**
  Active antismoking counseling
  **Exercise**
  Encourage activity
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BMI, body mass index; BP, blood pressure; TG, triglycerides; HbA1C, glycated hemoglobin.

**Notes:** ^a^Normal BMI values for age and sex: [@b46-vhrm-4-0825];

^b^[@b48-vhrm-4-0825];

^c^[@b49-vhrm-4-0825];

^d^[@b4-vhrm-4-0825];

^e^[@b5-vhrm-4-0825].
